Podcasts about Cancer Institute

JCO PO author Dr. Shilpa Gupta at Cleveland Clinic Children's Hospital shares insights into her article, "Fibroblast Growth Factor Receptor 3 (FGFR3) Alteration Status and Outcomes on Immune Checkpoint Inhibitors (ICPI) in Patients with Metastatic Urothelial Carcinoma". Host Dr. Rafeh Naqash and Dr. Gupta discuss how FGFR3 combined with TMB emerged as a biomarker that may be predictive for response to ICPI in mUC. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO Precision Oncology and Associate Professor at the OU Health Stephenson Cancer Center. Today I am excited to be joined by Dr. Shilpa Gupta, Director of Genitourinary Medical Oncology at the Cancer Institute and co-leader of the GU Oncology Program at the Cleveland Clinic, and also lead author of the JCO PO article titled "Fibroblast Growth Factor Receptor 3 Alteration Status and Outcomes on Immune Checkpoint Inhibitors in Patients With Metastatic Urothelial Carcinoma." At the time of this recording, our guest's disclosures will be linked in the transcript. Shilpa, welcome again to the podcast. Thank you for joining us today. Dr. Shilpa Gupta: Thank you, Rafeh. Honor to be here with you again. Dr. Rafeh Naqash: It is nice to connect with you again after two years, approximately. I think we were in our infancy of our JCO PO podcast when we had you first time, and it has been an interesting journey since then. Dr. Shilpa Gupta: Absolutely. Dr. Rafeh Naqash: Well, excited to talk to you about this article that you published. Wanted to first understand what is the genomic landscape of urothelial cancer in general, and why should we be interested in FGFR3 alterations specifically? Dr. Shilpa Gupta: Bladder cancer or urothelial cancer is a very heterogeneous cancer. And while we find there is a lot of mutations can be there, you know, like BRCA1, 2, in HER2, in FGFR, we never really understood what is driving the cancer. Like a lot of old studies with targeted therapies did not really work. For example, we think VEGF can be upregulated, but VEGF inhibitors have not really shown definite promise so far. Now, FGFR3 receptor is the only therapeutic target so far that has an FDA approved therapy for treating metastatic urothelial cancer patients, and erdafitinib was approved in 2019 for patients whose tumors overexpressed FGFR3 mutations, alterations, or fusions. And in the landscape of bladder cancer, it is important because in patients with non-muscle invasive bladder cancer, about 70 to 80% patients can have this FGFR3. But as patients become metastatic, the alterations are seen in, you know, only about 10% of patients. So the clinical trials that got the erdafitinib approved actually used archival tumor from local cancer. So when in the real world, we don't see a lot of patients if we are trying to do metastatic lesion biopsies. And why it is important to know this is because that is the only targeted therapy available for our patients right now. Dr. Rafeh Naqash: Thank you for giving us that overview. Now, on the clinical side, there is obviously some interesting data for FGFR3 on the mutation side and the fusion side. In your clinical practice, do you tend to approach these patients differently when you have a mutation versus when you have a fusion? Dr. Shilpa Gupta: We can use the treatment regardless of that. Dr. Rafeh Naqash: I recently remember I had a patient with lung cancer, squamous lung cancer, who also had a synchronous bladder mass. And the first thought from multiple colleagues was that this is metastatic lung. And interestingly, the liquid biopsy ended up showing an FGFR3-TACC fusion, which we generally don't see in squamous lung cancers. And then eventually, I was able to convince our GU colleagues, urologists, to get a biopsy. They did a transurethral resection of this tumor, ended up being primary urothelial and synchronous lung, which again, going back to the FGFR3 story, I saw in your paper there is a mention of FGFR3-TACC fusions. Anything interesting that you find with these fusions as far as biology or tumor behavior is concerned? Dr. Shilpa Gupta: We found in our paper of all the patients that were sequenced that 20% had the pathognomonic FGFR3 alteration, and the most common were the S249C, and the FGFR3-TACC3 fusion was in 45 patients. And basically I will say that we didn't want to generate too much as to fusion or the differences in that. The key aspect of this paper was that historically there were these anecdotal reports saying that patients who have FGFR alterations or mutations, they may not respond well to checkpoint inhibitors because they have the luminal subtype. And these were backed by some preclinical data and small anecdotal reports. But since then, we have seen that, and that's why a lot of people would say that if somebody's tumor has FGFR3, don't give them immunotherapy, give them erdafitinib first, right? So then we had this Phase 3 trial called the THOR trial, which actually showed that giving erdafitinib before pembrolizumab was not better. That debunked that myth, and we are actually reiterating that because in our work we found that patients who had FGFR3 alterations or fusions, and if they also have TMB-high, they actually respond very well to single agent immunotherapy. And that is, I think, very important because it tells us that we are not really seeing that so-called potential of resistance to immunotherapy in these patients. So to answer your question, yeah, we did see those differences, but I wouldn't say that any one marker is more prominent. Dr. Rafeh Naqash: The analogy is kind of similar to what we see in lung cancer with these mutations called STK11/KEAP1, which are also present in some other tumors. And one of the questions that I don't think has been answered is when you have in lung cancer, if you extrapolate this, where doublet or single agent immunotherapy doesn't do as well in tumors that are STK11 mutated. But then if you have a high TMB, question is does that TMB supersede or trump the actual mutation? Could that be one reason why you see the TMB-high but FGFR3 altered tumors in your dataset responding or having better outcomes to immunotherapy where potentially there is just more neoantigens and that results in a more durable or perhaps better response to checkpoint therapy? Dr. Shilpa Gupta: It could be. But you know, the patients who have FGFR alterations are not that many, right? So we have already seen that just patients with TMB-high respond very well to immunotherapy. Our last podcast was actually on that, regardless of PD-L1 that was a better predictor of response to immunotherapy. So I think it's not clear if this is adding more chances of response or not, because either way they would respond. But what we didn't see, which was good, that if they had FGFR3, it's not really downplaying the fact that they have TMB-high and that patients are not responding to immunotherapy. So we saw that regardless, and that was very reassuring. Dr. Rafeh Naqash: So if tomorrow in your clinic you had an individual with an FGFR3 alteration but TMB-high, I guess one could be comfortable just going ahead with immunotherapy, which is what the THOR trial as you mentioned. Dr. Shilpa Gupta: Yes, absolutely. And you know, when you look at the toxicity profiles of pembrolizumab and erdafitinib, really patients really struggle with using the FGFR3 inhibitors. And of course, if they have to use it, we have to, and we reserve it for patients. But it's not an easy drug to tolerate. Currently the landscape is such that, you know, frontline therapy has now evolved with an ADC and immunotherapy combinations. So really if patients progress and have FGFR3 alterations, we are using erdafitinib. But let's say if there were a situation where a patient has had chemotherapy, no immunotherapy, and they have FGFR3 upregulation and TMB-high, yes, I would be comfortable with using only pembrolizumab. And that really ties well together what we saw in the THOR trial as well. Dr. Rafeh Naqash: Going to the clinical applications, you mentioned a little bit of this in the manuscript, is combination therapies. You alluded to it a second back. Everything tends to get combined with checkpoint therapy these days, as you've seen with the frontline urothelial, pembrolizumab with an ADC. What is the landscape like as far as some of these FGFR alterations are concerned? Is it reasonable to combine some of those drugs with immune checkpoint therapy? And what are some of the toxicity patterns that you've potentially seen in your experience? Dr. Shilpa Gupta: So there was indeed a trial called the NORSE trial. It was a randomized trial but not a comparative cohort, where they looked at FGFR altered patients. And when they combined erdafitinib plus cetrelimab, that did numerically the response rates were much higher than those who got just erdafitinib. So yeah, the combination is definitely doable. There is no overlapping toxicities. But unfortunately that combination has not really moved forward to a Phase 3 trial because it's so challenging to enroll patients with such kind of rare mutations on large trials, especially to do registration trials. And since then the frontline therapy has evolved to enfortumab vedotin and pembrolizumab. I know there is an early phase trial looking at a next generation FGFR inhibitor. There is a triplet combination looking in Phase 1 setting with a next generation FGFR inhibitor with EV-pembro. However, it's not a randomized trial. So you know, I worry about such kinds of combinations where we don't have a path for registration. And in the four patients that have been treated, four or five patients in the early phase as a part of basket trial, the toxicities were a lot, you know, when you combine the EV-pembro and an FGFR3 inhibitor, we see more and more toxicity. So the big question is do we really need the "kitchen sink" approach when we have a very good doublet, or unless the bar is so high with the doublet, like what are we trying to add at the expense of patient toxicity and quality of life is the big question in my mind. Dr. Rafeh Naqash: Going back to your manuscript specifically, there could be a composite biomarker. You point out like FGFR in addition to FGFR TMB ends up being predictive prognostic there. So that could potentially be used as an approach to stratify patients as far as treatment, whether it's a single agent versus combination. Maybe the TMB-low/FGFR3 mutated require a combination, but the TMB-high/FGFR mutated don't require a combination, right? Dr. Shilpa Gupta: No, that's a great point, yeah. Dr. Rafeh Naqash: But again, very interesting, intriguing concepts that you've alluded to and described in this manuscript. Now, a quick take on how things have changed in the bladder cancer space in the last two years. We did a podcast with you regarding some biomarkers as you mentioned two years back. So I really would like to spend the next minute to two to understand how have things changed in the bladder cancer space? What are some of the exciting things that were not there two years back that are in practice now? And how do you anticipate the next two years to be like? Maybe we'll have another podcast with you in another two years when the space will have changed even more. Dr. Shilpa Gupta: Certainly a lot has happened in the two years, you know. EV-pembro became the universal frontline standard, right? We have really moved away from cisplatin eligibility in metastatic setting because anybody would benefit from EV-pembro regardless of whether they are candidates for cisplatin or not, which historically was relevant. And just two days ago, we saw that EV-pembro has now been approved for localized bladder cancer for patients who are cisplatin ineligible or refusing. So, you know, this very effective regimen moving into earlier setting, we now have to really think of good treatment options in the metastatic setting, right? So I think that's where a lot of these novel combinations may come up. And what else we've seen is in a tumor agnostic trial called the DESTINY-PanTumor trial, patients who had HER2 3+ on immunohistochemistry, we saw the drug approval for T-DXd, and I think that has kind of reinvigorated the interest in HER2 in bladder cancer, because in the past targeting HER2 really didn't work. And we still don't know if HER2 is a driver or not. And at ESMO this year, we saw an excellent study coming out of China with DV which is targeting HER2, and toripalimab, which is a Chinese checkpoint inhibitor, showing pretty much similar results to what we saw with EV-pembro. Now, you know, not to do cross-trial comparisons, but that was really an amazing, amazing study. It was in the presidential session. And I think the big question is: does that really tell us that HER2-low patients will not benefit? Because that included 1+, 2+, 3+. So that part we really don't know, and I think we want to study from the EV-302 how the HER2 positive patients did with EV and pembro. So that's an additional option, at least in China, and hopefully if it gets approved here, there is a trial going on with DV and pembro. And lastly, we've seen a very promising biomarker, like ctDNA, for the first time in bladder cancer in the adjuvant setting guiding treatment with adjuvant atezolizumab. So patients who were ctDNA positive derived overall survival and recurrence-free survival benefit. So that could help us select moving forward with more studies. We can spare unnecessary checkpoint inhibitors in patients who are not going to benefit. So I think there is a lot happening in our field, and this will help do more studies because we already have the next generation FGFR inhibitors which don't have the toxicities that erdafitinib comes with. And combining those with these novel ADCs and checkpoint inhibitors, you know, using maybe TMB as a biomarker, because we really need to move away from PD-L1 in bladder cancer. It's shown no utility whatsoever, but TMB has. Dr. Rafeh Naqash: Well, thank you so much, Shilpa, for that tour de force of how things have changed in bladder cancer. There used to be a time when lung and melanoma used to lead this space in terms of the number of approvals, the biomarker development. It looks like bladder cancer is shifting the trend at this stage. So definitely exciting to see all the new changes that are coming up. I'd like to spend another minute and a half on your career. You've obviously been a leader and example for many people in the GU space and beyond. Could you, for the sake of our early career especially, the trainees and other listeners, describe how you focused on things that you're currently leading as a leader, and how you shaped your career trajectory over the last 10 years? Dr. Shilpa Gupta: That's a really important question, Rafeh, and you and I have had these discussions before, you know, being an IMG on visas like you, and being in different places. I think I try to make the most of it, you know, instead of focusing on the setbacks or the negative things. Like tried to grab the opportunities that came along. When I was at Moffitt, got to get involved with the Phase 1 trial of pembrolizumab in different tumor types. And just keeping my options open, you know, getting into the bladder cancer at that time when I wanted to really do only prostate, but it was a good idea for me to keep my options open and got all these opportunities that I made use of. I think an important thing is to, like you said, you know, have a focus. So I am trying to focus more on biomarkers that, you know, we know that 70% patients will respond to EV-pembro, right? But what about the remaining 30%? Like, so I'm really trying to understand what determines hyperprogressors with such effective regimens who we really struggle with in the clinic. They really don't do well with anything we give them after that. So we are doing some work with that and also trying to focus on PROs and kind of patient-reported outcomes. And a special interest that I've now developed and working on it is young-onset bladder cancer. You know, the colorectal cancer world has made a lot of progress and we are really far behind. And bladder cancer has historically been a disease of the elderly, which is not the case anymore. We are seeing patients in their 30s and 40s. So we launched this young-onset bladder cancer initiative at a Bladder Cancer Advocacy Network meeting and now looking at more deep dive and creating a working group around that. But yeah, you know, I would say that my philosophy has been to just take the best out of the situation I'm in, no matter where I am. And it has just helped shape my career where I am, despite everything. Dr. Rafeh Naqash: Well, thank you again. It is always a pleasure to learn from your experiences and things that you have helped lead. Appreciate all your insights, and thank you for publishing with JCO PO. Hopefully we will see more of your biomarker work being published and perhaps bring you for another podcast in a couple of years. Dr. Shilpa Gupta: Yeah, thank you, Rafeh, for the opportunity. And thanks to JCO PO for making these podcasts for our readers. So thanks a lot. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. DISCLOSURES Dr. Shilpa Gupta Stock and Other Ownership Interests: Company: BioNTech SE,  Nektar Consulting or Advisory Role: Company: Gilead Sciences, Pfizer, Merck, Foundation Medicine, Bristol-Myers Squibb/Medarex, Natera, Astellas Pharma, AstraZeneca, Novartis, Johnson & Johnson/Janssen Research Funding: Recipient: Your Institution Company: Bristol Myers Squibb Foundation, Merck, Roche/Genentech, EMD Serono, Exelixis, Novartis, Tyra Biosciences, Pfizer, Convergent Therapeutics, Acrivon Therapeutics, Flare Therapeutics, Amgen Travel, Accommodations, Expenses: Company: Pfizer, Astellas Pharma, Merck    

Dr. Lisa Duhaime is a board-certified medical oncologist at Peeples Cancer Institute at Hamilton Medical Center in Dalton, Georgia.For more information about Peeples Cancer Institute, call 844-PCI-HOPE or visit VitruvianHealth.com/cancer.This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.

More than 400,000 children and adolescents will be diagnosed with cancer worldwide this year. Many treatments that are meant to save a child can leave them with lifelong side-effects, including heart damage, infertility and cognitive issues. But for the first time, precision medicine is using the tiniest tools – nanoparticles – to design tailor-made treatments to beat childhood cancer. Tune in to learn how precision medicine is changing the odds in the fight against childhood cancer with Professor Maria Kavallaris AM, a researcher whose own cancer diagnosis occurred at the same time as a career-changing opportunity to join the Children's Cancer Institute.See omnystudio.com/listener for privacy information.

In this episode, Dr. James McGee shares how OSF HealthCare is expanding access to advanced cancer therapies, including proton therapy, flash radiation, and innovative brachytherapy techniques. He also discusses the institute's push toward personalized risk assessment, early detection, and bringing cutting edge research to rural communities.

An interview with Dr. Bryan Bell with Providence Cancer Institute and Dan Floyd with Hood To Coast about the advancements in cancer research, how AI is helping further outcomes, and how Hood To Coast raises money and awareness of the institute.

Dr. Jeanine Cook-Garard and Pandora Groth learn about clinical trials, especially concerning phase 1, or early-stage trial in oncology.  They speak with Dr. Geraldine O'Sullivan Coyne, who was recently named to lead The Northwell Cancer Institute START Center for Cancer Research - the first site in New York, expanding the community-based early-phase oncology research network.  Northwell's START unit is located at the R.J. Zuckerberg Cancer Center in New Hyde Park. Dr. O'Sullivan Coyne joins Northwell Health after two years as a clinical investigator at START Dublin in Ireland, and 10 years at the National Cancer Institute in Maryland.

On this episode, Dr. Jun Zhang, Vice President of Oncology Research at the OSF HealthCare Cancer Institute, joins the podcast to discuss expanding cancer research programs, the importance of instilling a patient-centric mission, breakthroughs in cancer research, and his advice for emerging leaders in healthcare.

Dr. Adrian Miller is a board-certified, fellowship trained radiologist in breast imaging at Peeples Cancer Institute at Hamilton Medical Center in Dalton, Georgia.For more information about Peeples Cancer Institute, call 844-PCI-HOPE or visit VitruvianHealth.com/cancer.This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.

Dr. Adrian Miller is a board-certified, fellowship trained radiologist in breast imaging at Peeples Cancer Institute at Hamilton Medical Center in Dalton, Georgia.For more information about Peeples Cancer Institute, call 844-PCI-HOPE or visit VitruvianHealth.com/cancer.This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.

Dr. Adrian Miller is a board-certified, fellowship trained radiologist in breast imaging at Peeples Cancer Institute at Hamilton Medical Center in Dalton, Georgia.For more information about Peeples Cancer Institute, call 844-PCI-HOPE or visit VitruvianHealth.com/cancer.This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.

El Dra. Adrian Miller es radiólogo certificado y con especialización en imágenes mamarias en el Instituto Oncológico Peeples del Centro Médico Hamilton en Dalton, Georgia. Para obtener más información sobre el Instituto Oncológico Peeples, llame al 844-PCI-HOPE o visite VitruvianHealth.com/cancer.Este programa no pretende diagnosticar ni tratar enfermedades ni reemplazar la atención médica profesional. Si tiene algún problema de salud, consulte a su profesional de la salud.

El Dra. Adrian Miller es radiólogo certificado y con especialización en imágenes mamarias en el Instituto Oncológico Peeples del Centro Médico Hamilton en Dalton, Georgia. Para obtener más información sobre el Instituto Oncológico Peeples, llame al 844-PCI-HOPE o visite VitruvianHealth.com/cancer.Este programa no pretende diagnosticar ni tratar enfermedades ni reemplazar la atención médica profesional. Si tiene algún problema de salud, consulte a su profesional de la salud.

El Dra. Adrian Miller es radiólogo certificado y con especialización en imágenes mamarias en el Instituto Oncológico Peeples del Centro Médico Hamilton en Dalton, Georgia. Para obtener más información sobre el Instituto Oncológico Peeples, llame al 844-PCI-HOPE o visite VitruvianHealth.com/cancer.Este programa no pretende diagnosticar ni tratar enfermedades ni reemplazar la atención médica profesional. Si tiene algún problema de salud, consulte a su profesional de la salud.

"I remember my dad chasing a brown snake through the back yard in his underwear" - Jamie Durie In this episode of Three Food Memories, Savva sits down with Jamie Durie at his house in Avalon, surrounded by 50 guests (and more than 250 indoor plants). On the menu is tuna sashimi in Kyoto, caribou carpaccio in Hudson Bay, and risotto alla Milanese, along with fond recollections of his youth in Tom Price, his acrobatic Manpower days, fatherhood, meeting Barack Obama, working with Oprah, his landscape and furniture design, how we can all make our homes a little more environmentally friendly, as well as the moment that took him from hot pants to pot plants (which may or may not have something to do with Molly Meldrum).Jamie's social cause is the Children's Cancer Institute, because every child should get the chance to grow up and grow old. But cancer cuts life short for hundreds of children every year. In Australia alone, every week, three young lives will be lost to the disease. For over 40 years, Children's Cancer Institute has been researching the causes, prevention and cure of childhood cancer.This episode is thanks to the team at Saint Cloche Atelier - saintcloche.com/pages/atelierSend us a textTo find out more about the project and Savva - head to threefoodmemories.comInsta - @savvasavas @threefoodmemoriesEmail us at threefoodmemories@plated.com.au, we'd love to hear from you! TFM is produced and edited by Lauren McWhirter with original music by Russell Torrance.

As we mark Breast Cancer Awareness Month, Professor John Kennedy of the Trinity St James's Cancer Institute warns cancer patients are being let down, with just 3 of 28 national targets met and thousands facing dangerous delays for tests and treatment. He joins Anton to discuss.

At Sarasota Memorial, the multi-disciplinary cancer care team provides prostate screening and diagnostic biopsy services, along with comprehensive care. Kunal Saigal, MD, Medical Director of Radiation Oncology at the Brian D. Jellison Cancer Institute, discusses the latest advancements in prostate cancer treatment, including the use of Pluvicto.You can also watch the video recording on our Vimeo channel here.For more health tips & news you can use from experts you trust, sign up for Sarasota Memorial's monthly digital newsletter, Healthe-Matters.

Los ahorradores hemáticos son un recurso clave para garantizar una cirugía oncológica más segura y con menor riesgo de complicaciones. La Dra. Brenda Pastrana, Cirujana Oncólogo certificada en Cancún Cancer Institute y especialista en Cancún Oncology Center, explica que estos medicamentos ayudan a reducir el sangrado durante procedimientos quirúrgicos, lo que permite una recuperación más rápida y efectiva. Entre ellos destaca el ácido tranexámico, una molécula sintetizada en la década de 1940 por la doctora Utako Okamoto, inicialmente utilizada para disminuir el sangrado posparto en mujeres. Hoy en día, este fármaco se emplea ampliamente en cirugías oncológicas para disminuir la necesidad de transfusiones y mejorar la seguridad del paciente. Conocer las opciones de ahorradores hemáticos, ya sean sintéticos, de origen animal o vegetal como la vitamina K, resulta fundamental para ofrecer a cada paciente un tratamiento quirúrgico personalizado y con los más altos estándares de calidad.La Dra. Brenda Pastrana te invita a escuchar el #podcast para conocer más del tema. ¡No te pierdas sus recomendaciones! ¡Disfruta del episodio 280 y continúa escuchando cada uno de nuestros #PodcastsMédicos  preparados especialmente para ti!➡️ ENLACES DE INTERÉSOtros episodios de Actitud Saludable | Mínima Invasión en Oncología

WLKY featured a story on former pediatric cancer patient Seth Walsh and how he's giving back collecting donations for the Norton Children's Cancer Institute food pantry. FULL STORY: https://www.wdjx.com/former-radiothon-kid-gives-back-to-norton-childrens-hospital/

GDP Script/ Top Stories for July 24th Publish Date: July 24th From the BG AD Group Studio Welcome to the Gwinnett Daily Post Podcast. Today is Thursday, July 24th and Happy birthday to Barry Bonds I’m Peyton Spurlock and here are your top stories presented by KIA Mall of Georgia. Northside Hospital Cancer Institute acquires Snellville radiation oncology clinic Gwinnett schools will roll out weapons detection systems in August Gwinnett student places third at Microsoft Office Specialist National Championship Plus, Leah McGrath from Ingles Markets on diabetes All of this and more is coming up on the Gwinnett Daily Post podcast, and if you are looking for community news, we encourage you to listen daily and subscribe! Break 1: 07.14.22 KIA MOG STORY 1: Northside Hospital Cancer Institute acquires Snellville radiation oncology clinic Northside Hospital's Cancer Institute has expanded its network by acquiring five radiation oncology clinics, including one in Snellville, enhancing access to advanced cancer treatments in south Gwinnett. The Snellville clinic, located at 1770 Presidential Circle, joins locations in Decatur, Covington, Conyers, and Blairsville. Northside officials emphasize the convenience and quality of care provided by their multidisciplinary team, offering techniques like external beam radiation and stereotactic radiosurgery. The clinics will retain their existing providers and services, ensuring continuity and compassionate care for patients. STORY 2: Gwinnett schools will roll out weapons detection systems in August Gwinnett County Public Schools will roll out weapons detection systems in all middle and high schools starting later in August, following a $19.3 million investment approved by the school board. These systems aim to enhance safety after last year’s Apalachee High School shooting. The devices, already used in athletic venues, will be installed at multiple entrances for morning intake and at main entrances during school hours. The district is also hiring 15 additional school resource officers for elementary schools, working toward a long-term goal of one officer per school. This initiative is part of a three-pronged safety approach focusing on prevention, protection, and response. STORY 3: Gwinnett student places third at Microsoft Office Specialist National Championship Allena Nguyen, a rising junior at Gwinnett Online Campus, earned third place in the 2025 Certiport Microsoft Office Specialist National Championship, competing in the Microsoft PowerPoint category. She was the only Georgia resident to place, winning a $1,000 cash prize. Nguyen excelled at the Georgia Spring Qualifier with perfect scores and the fastest times, earning her a spot among 187 national contestants. Principal Bo Ford praised her dedication and passion for technology, highlighting her as a role model for student success. We have opportunities for sponsors to get great engagement on these shows. Call 770.874.3200 for more info. We’ll be right back Break 2: DTL MOVIE CLUB And now here is Leah McGrath from Ingles Markets on diabetes STORY 6: Shane Foye of Peachtree Cornes named to UGA's 40 Under 40 Class of 2025 The University of Georgia has announced its 40 Under 40 Class of 2025, honoring young alumni for their achievements in various fields, including medicine, sports, and space exploration. Among the honorees is Shane Foye of Peachtree Corners, president of DW1 and an active UGA supporter. The group will be celebrated at a September awards luncheon on campus. Selected from hundreds of nominations, these alumni embody UGA’s principles of wisdom, justice, and moderation, showcasing the university’s impact on their success and contributions to their communities. STORY 7: Gwinnett County to host Household Hazardous Waste Collection Day Saturday Gwinnett County's Household Hazardous Waste Collection Day returns on July 26 at the Gwinnett County Fairgrounds from 8 a.m. to noon. Co-hosted by Gwinnett Clean & Beautiful and the Department of Water Resources, the event helps residents safely dispose of hazardous items like paints, batteries, and pesticides. Volunteers are needed to assist with traffic and material handling. Residents can bring up to five containers of waste for free, but items like ammunition, biohazard waste, and electronics will not be accepted. The event has grown significantly, with over 1,000 vehicles attending in February. Break 3: We’ll have closing comments after this Break 4: Ingles Markets 7 Signoff – Thanks again for hanging out with us on today’s Gwinnett Daily Post Podcast. If you enjoy these shows, we encourage you to check out our other offerings, like the Cherokee Tribune Ledger Podcast, the Marietta Daily Journal, or the Community Podcast for Rockdale Newton and Morgan Counties. Read more about all our stories and get other great content at www.gwinnettdailypost.com Did you know over 50% of Americans listen to podcasts weekly? Giving you important news about our community and telling great stories are what we do. Make sure you join us for our next episode and be sure to share this podcast on social media with your friends and family. Add us to your Alexa Flash Briefing or your Google Home Briefing and be sure to like, follow, and subscribe wherever you get your podcasts. Produced by the BG Podcast Network Show Sponsors: ingles-markets.com kiamallofga.com #NewsPodcast #CurrentEvents #TopHeadlines #BreakingNews #PodcastDiscussion #PodcastNews #InDepthAnalysis #NewsAnalysis #PodcastTrending #WorldNews #LocalNews #GlobalNews #PodcastInsights #NewsBrief #PodcastUpdate #NewsRoundup #WeeklyNews #DailyNews #PodcastInterviews #HotTopics #PodcastOpinions #InvestigativeJournalism #BehindTheHeadlines #PodcastMedia #NewsStories #PodcastReports #JournalismMatters #PodcastPerspectives #NewsCommentary #PodcastListeners #NewsPodcastCommunity #NewsSource #PodcastCuration #WorldAffairs #PodcastUpdates #AudioNews #PodcastJournalism #EmergingStories #NewsFlash #PodcastConversationsSee omnystudio.com/listener for privacy information.

Human Papillomavirus (HPV) is a small DNA virus that infects skin and wet surfaces of the body. The virus is typically spread through vaginal, anal, or oral sex. There are over 100 different types of HPV. The most common types of HPV are found on the skin and appear as warts. It is one of the most common types of sexually transmitted infections worldwide. HPV is responsible for more than 90% of anal and cervical cancers. The high-risk types of HPV form in the back of the throat, also known as Oropharyngeal Cancer. Vivian F. Wu, MD, MPH, is a surgeon-scientist specializing in all cancers of the head and neck, including those of the tongue, throat, voice box, thyroid, skin, and salivary glands. She is the Director of the Head and Neck Cancer Center of Excellence at Saint John's Cancer Institute and Pacific Neuroscience Institute (PNI).

Dr. Arif Ali is a board-certified radiation oncologist at Peeples Cancer Institute at Hamilton Medical Center in Dalton, Georgia.For more information about Peeples Cancer Institute, call 844-PCI-HOPE or visit VitruvianHealth.com/cancer.This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.

El Dr. Arif Ali es un oncólogo radioterapeuta certificado por la junta del Peeples Cancer Institute en Dalton, Georgia.Para obtener más información sobre Peeples Cancer Institute, llame al 844-PCI-HOPE o visite VitruvianHealth.com/cancer.Este programa de ninguna manera busca diagnosticar o tratar enfermedades o reemplazar la atención médica profesional. Consulte a su proveedor de atención médica si tiene un problema de salud.

Dr. Arif Ali is a board-certified radiation oncologist at Peeples Cancer Institute at Hamilton Medical Center in Dalton, Georgia.For more information about Peeples Cancer Institute, call 844-PCI-HOPE or visit VitruvianHealth.com/cancer.This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.

El Dr. Arif Ali es un oncólogo radioterapeuta certificado por la junta del Peeples Cancer Institute en Dalton, Georgia.Para obtener más información sobre Peeples Cancer Institute, llame al 844-PCI-HOPE o visite VitruvianHealth.com/cancer.Este programa de ninguna manera busca diagnosticar o tratar enfermedades o reemplazar la atención médica profesional. Consulte a su proveedor de atención médica si tiene un problema de salud.

Dr. Arif Ali is a board-certified radiation oncologist at Peeples Cancer Institute at Hamilton Medical Center in Dalton, Georgia.For more information about Peeples Cancer Institute, call 844-PCI-HOPE or visit VitruvianHealth.com/cancer.This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.

Professor John Kennedy, Medical Director of Trinity St James' Cancer Institute discusses the significance of being designated the country's first comprehensive cancer centre.

Vivian F. Wu, MD, MPH, is a surgeon-scientist specializing in all cancers of the head and neck, including those of the tongue, throat, voice box, thyroid, skin, and salivary glands. She is the Director of the Head and Neck Cancer Center of Excellence at Saint John's Cancer Institute and Pacific Neuroscience Institute (PNI).Dr. Wu earned her medical degree from Howard University and completed her residency at Oregon Health & Science University. She pursued fellowship training at the University of Michigan. She also holds a Masters in Public Health from Yale University. With over a decade of experience, she provides advanced treatments such as minimally invasive thyroid surgery, transoral robotic surgery, and sentinel node biopsy skin and oral cavity cancers.A believer in multidisciplinary care, Dr. Wu collaborates with experts in oncology, radiation, endocrinology, and dermatology. She is an advocate for HPV vaccination and a former Vice Chair of Research. Dr. Wu is dedicated to improving patient outcomes through innovative care and research, compassionately treating patients at Pacific Head & Neck, Pacific Neuroscience Institute in Southern California.

A powerful rallying cry to protect the world's oceans has been issued from Sir David Attenborough.His message features in a new film, Ocean with David Attenborough, which opens in cinemas across the world today.Plus, Owkin has launched K Navigator, an AI-powered research co-pilot designed to revolutionise biomedical science.They say the technology is an “agentic playground” where researchers can explore, refine, and validate a theory, therefore accelerating the quality and pace of their discoveries.According to the Faculty of Pharmaceutical Medicine, it takes around 12 years for a laboratory discovery to become an approved medicine. There is also a high failure rate.Tech and Science Daily spoke to Dr Ingo Ringshausen, a consultant at University College London Hospital who runs a research group for the Cancer Institute and—importantly—was also one of the first to test the technology.Also in this episode:Could Nasa switch up and launch to Mars as early as 2026?London NHS worker awarded £29,000 after being likened to Darth VaderIs Scotland home to the world's oldest football pitch? Hosted on Acast. See acast.com/privacy for more information.

Dr. Jason Williams, President and Director of Interventional Oncology and Immunotherapy at the Williams Cancer Institute, uses a combination of Pulse Electric Field technology to ablate tumors and direct injection of immunotherapy drugs into the tumor to stimulate the immune system. This approach can be used in conjunction with traditional cancer treatments and has fewer side effects than standard immunotherapy. This method is part of the broader trend in cancer research to provide a more targeted approach to treating tumors. Jason explains, "Our big focus is going to the tumor itself, so we do treatments directly at the tumor, and we do a combination of things. We do things that will be considered ablation where we're using different technologies or energies — I'll explain — particularly, we use one called Pulse Electric Field (PEF), which kills the tumor by essentially shocking it, and that kills it in a way that actually makes the immune system see it better. You're not trying to kill all of the tumor, you're trying to kill pieces for the immune system. Then we inject drugs into that area of the tumor, particularly immunotherapy drugs, but it can be other drugs as well, and just really taking the fight to the cancer right in the tumor." "I think that our mistake in cancer treatments is that we're not addressing the tumors directly. I mean, it's one thing to expect that you're going to take a drug orally or intravenously and that it's going to arrive and make it to the cancer cells. Still, the other way is to go right into it, putting the drugs there, and particularly with immunotherapies, where you want to attract the immune system to it. You want those drugs in the cancer, you don't want them just everywhere in the body." #WilliamsCancer #Cancer #Oncology #Tumors #Immunotherapy #PulseElectricField #ImmuneSystem #TargetingTumors WilliamsCancerInstitute.com Download the transcript here

Dr. Jason Williams, President and Director of Interventional Oncology and Immunotherapy at the Williams Cancer Institute, uses a combination of Pulse Electric Field technology to ablate tumors and direct injection of immunotherapy drugs into the tumor to stimulate the immune system. This approach can be used in conjunction with traditional cancer treatments and has fewer side effects than standard immunotherapy. This method is part of the broader trend in cancer research to provide a more targeted approach to treating tumors. Jason explains, "Our big focus is going to the tumor itself, so we do treatments directly at the tumor, and we do a combination of things. We do things that will be considered ablation where we're using different technologies or energies — I'll explain — particularly, we use one called Pulse Electric Field (PEF), which kills the tumor by essentially shocking it, and that kills it in a way that actually makes the immune system see it better. You're not trying to kill all of the tumor, you're trying to kill pieces for the immune system. Then we inject drugs into that area of the tumor, particularly immunotherapy drugs, but it can be other drugs as well, and just really taking the fight to the cancer right in the tumor." "I think that our mistake in cancer treatments is that we're not addressing the tumors directly. I mean, it's one thing to expect that you're going to take a drug orally or intravenously and that it's going to arrive and make it to the cancer cells. Still, the other way is to go right into it, putting the drugs there, and particularly with immunotherapies, where you want to attract the immune system to it. You want those drugs in the cancer, you don't want them just everywhere in the body." #WilliamsCancer #Cancer #Oncology #Tumors #Immunotherapy #PulseElectricField #ImmuneSystem #TargetingTumors WilliamsCancerInstitute.com Listen to the podcast here

Tom Cox, Vice President of Operations, and Tenille Oderwald, Director of Operations at OSF HealthCare Cancer Institute, discuss how advancements in brachytherapy and proton therapy are enhancing cancer care. They highlight the importance of thorough risk assessment processes for patients, the value of compassionate staff dedicated to patient needs, and the critical role of post-treatment care resources in improving outcomes.

Tom Cox, Vice President of Operations, and Tenille Oderwald, Director of Operations at OSF HealthCare Cancer Institute, discuss how advancements in brachytherapy and proton therapy are enhancing cancer care. They highlight the importance of thorough risk assessment processes for patients, the value of compassionate staff dedicated to patient needs, and the critical role of post-treatment care resources in improving outcomes.

Jame Abraham, MD, FACP, Chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic Cancer Institute, discusses the continued recruitment of doctors and the strong support of team members as the clinic expands. He highlights progress in clinical and research efforts, along with strategies to support the team amid an influx of patients and the evolving impact of AI in healthcare.

Virology vanguard Dr. Bob Gallo is far from ready to slow down. Now in his seventh decade as one of America's top scientists, he could easily sit back and enjoy the fruits of his numerous and pioneering achievements. His groundbreaking work began in the 1970s with research into human retroviruses, including the discovery of the T-cell growth factor (IL-2) and the identification of the Human T-Cell Lymphotropic Virus (HTLV-1) in 1980, earning him his first Lasker Award, often referred to as “America's Nobel Prize.” His subsequent research led to the identification of HIV-1 as the cause of AIDS, securing him a second Lasker Award. In the 1980s, he was the world's most cited scientist. Along with his team, he developed the first HIV blood test, crucial for understanding the spread of AIDS and managing HIV patients. In the mid 1990's Gallo and his collaborators discovered chemokines, naturally occurring compounds that were essential for understanding how HIV infects cells. Dr. Gallo later founded the Institute of Human Virology at the University of Maryland School of Medicine in 1996 and co-founded the Global Virus Network (GVN) in 2011 to enhance global virus detection and management. Recently, Dr. Gallo and his team moved to Tampa, the new global headquarters for GVN, where he now serves as director of the University of South Florida (USF) Virology Institute and Head of the Microbial Oncogenesis Program at the Cancer Institute at Tampa General Hospital (TGH).   In the first part of this wide-ranging interview, Dr. Gallo shares insights into his entry into virology and his initial research into the etiology of certain cancers. This work included crucial discoveries around T cell growth factors, paving the way for identifying HTLV-1. He discusses his collaboration with CDC epidemiologists, which led to recognizing AIDS as being caused by a retrovirus. Once the HIV virus was identified as the cause, creating the first blood test for HIV had profound impacts on the epidemic and patient care.   In the second segment, Dr. Gallo discusses the origins of the HIV virus and its early global spread. He also reflects on the COVID-19 pandemic, why the focus on its origins is irrelevant and reflects on how to rebuild public trust in science and medicine, which may have been damaged during the pandemic.   In the concluding segment, Dr. Gallo talks about his reasons for joining USF Health and TGH and the research areas he finds most promising going forward. He speculates on the prospects for an HIV vaccine, the impact of artificial intelligence on virology, and why he doesn't necessarily worry about the threat of the next global pandemic. Finally, Dr. Gallo opens up about how the early loss of his young sister deeply affected his life and his desired legacy. Dr Vega would like to thank her friend Job Meiller, her YES Man, for the wonderful musical contributions and coming through on every idea she has. This time he contributes his renditions of Bruce Springsteen's "Streets of Philadelphia" and "Your Song," by Elton John. Thank you Job! Thanks also to Dr. Ana Velez, our artistic contributor, for her painting, "HIV," used in our episode thumbnail.

In this episode, Dr. Boris C. Pasche, President and CEO at Karmanos Cancer Institute, delves into the latest advances in cancer treatment. He highlights exciting developments in theranostics, immunotherapy, and radiofrequency technologies, offering new hope for patients with advanced cancer. Dr. Pasche shares insights on how these therapies are transforming the future of oncology and improving patient outcomes.

For more information about Hamilton Health Care System's imaging services, visit HamiltonHealth.com/imaging. To make an appointment for imaging at Hamilton Diagnostics Center or a mammogram at People's Cancer Institute, call 706-272-6565. To learn more about Peeples Cancer Institute, visit HamiltonHealth.com/cancer.This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.

Para obtener más información sobre los servicios de imágenes de Hamilton Health Care System, visite HamiltonHealth.com/imaging. Para programar una cita para imágenes en Hamilton Diagnostics Center o una mamografía en People's Cancer Institute, llame al 706-272-6565. Para obtener más información sobre Peeples Cancer Institute, visite HamiltonHealth.com/cancer.Este programa de ninguna manera busca diagnosticar o tratar enfermedades ni reemplazar la atención médica profesional. Consulte a su proveedor de atención médica si tiene un problema de salud.

A website for the Prostate Cancer Institute of America:   www.prostatecancerusa.comDr, Ajay Bhatnagar: (33) Ajay Bhatnagar MD,MBA | LinkedIn A recent publication from our guest, Dr. Bhatnagar:Modern Low Dose Rate Brachytherapy For Prostate Cancer: A Comprehensive Guide for Urologists: Bhatnagar, Dr. Ajay, Koneru, Dr. Bobby N., Agarwal, Dr. Manuj, Wallner, Dr. Kent, Patel, Dr. Pratik: 9798338512012: Amazon.com: Books

In this episode, Dr. Aaron Spalding, Executive Medical Director at Norton Cancer Institute, discusses innovations in cancer care, the importance of coordinated care teams, and the future of early cancer detection. He also shares insights on leadership in healthcare, emphasizing the value of empathy and listening in both patient care and leadership roles.

In this episode, Laura Matthews, Vice President and Administrator at Inova Schar Cancer Institute, reflects on the institute's five-year milestone. She discusses the institute's rapid growth, the importance of maintaining patient access, and the innovative programs focused on cancer prevention and psychosocial support.

Ann Barshinger passed away at 100 years old, and leaves behind a lasting impact on the people she's served in Central Pennsylvania. Barshinger was known for her big heart and generosity. Over the years, she's donated millions to hospitals, colleges, churches, and many more organizations. Ann was also instrumental in the opening of Ann B. Barshinger Cancer Institute, part of Penn Medicine Lancaster General Health in 2013. Dr. Randall A. Oyer a founding executive medical director of the Ann B. Barshinger Cancer Institute said cancer never touched her family, but wanted to provide support to the families that we impacted by cancer. "People often ask Ann if she had cancer or if someone in her family had had cancer, and she said no. She had simply seen and felt the strain, the stress, the suffering that friends, or others that she knew had to deal with when they, faced the cancer diagnosis and she wanted to make sure that all cancer care was convenient with close to home, that people had better chances of being cured, and that people were treated like human beings, in their cancer treatment, "said Dr. Oyer. Megan Tomsheck is the Senior Vice President and Chief Development Officer with Vision Corps. Tomsheck has known Ann for 10 years says she lived to give, and her legacy will live on for generations to come. " So many times we'd be out having breakfast and somebody would come up and thank her for her support of the Cancer Institute, because they recognized her, because they had a family member who received services. So, it just to watch her little spark go throughout the community. And the ripple effect was was amazing to watch something I'll always be thankful for the opportunity to to be part of, "said Tomsheck. WITF was also a beneficiary of Ann's generosity. She had been a donor for over 20 years, and her foundation supported stipends for interns from York County, among other things.      Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

Dr. Lisa Duhaime is a board-certified medical oncologist at Peeples Cancer Institute in Dalton, Georgia.For more information about Peeples Cancer Institute, call 844-PCI-HOPE or visit HamiltonHealth.com/cancer.This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.

La Dra. Lisa Duhaime es oncóloga médica certificada por la junta del Peeples Cancer Institute en Dalton, Georgia.Para obtener más información sobre Peeples Cancer Institute, llame al 844-PCI-HOPE o visite HamiltonHealth.com/cancer.Este podcast de ninguna manera busca diagnosticar o tratar enfermedades o reemplazar la atención médica profesional. Consulte a su proveedor de atención médica si tiene un problema de salud. La versión en español es una traducción del original en inglés. En caso de discrepancia, prevalecerá el original en inglés (Health for Life: https://health-for-life.captivate.fm/listen).This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem. The Spanish version is a translation of the original in English. In case of a discrepancy, the English original (Health for Life: https://health-for-life.captivate.fm/listen) will prevail.

In this episode, Kip Lee, VP of Innovation & Product Strategy, University Hospitals, Brian Kovach, Vice President, Cancer Institute, MetroHealth, & Joseph Rich, Senior Director, Cleveland Clinic Innovations, all share insights into the focus and future of The Cleveland Innovation District from their perspective roles.

In this episode, Dr. John Deeken, President at Inova Schar Cancer Institute shares insights into his background, what trends & issues in healthcare he is keeping a close eye on, what traits the most effective healthcare leaders will need to be successful in the coming years, and more.

Dr. Guru Sonpavde, Medical Director of Genitourinary Oncology (GU), AdventHealth Cancer Institute joins the podcast to dive deep into some of the clinical research that AdventHealth is pioneering and the work around a new bladder cancer therapy vaccine that represents the forefront of precision oncology.

In this episode, Dr. Wassim McHayleh, Clinical Program Director for the Breast Cancer Program, AdventHealth Cancer Institute shares insights into his background, AdventHealth's Breast Multidisciplinary (MCD) Model, how the model benefits both patients and providers, advice for other systems adopting this model, and more.

In this episode, Daniel Arnold sits down with Dianne Keen, a healthcare education and marketing specialist with over 25 years of experience in Radiology Practice Development. Dianne shares her unexpected entry into radiology and her pivotal role in promoting interventional radiology (IR) procedures. After serving as the Director of Practice Development & Strategic Initiatives at Radiology Partners, she takes on the role of Vice President of Strategy and Growth for Abbadox, a healthcare software provider specializing in Radiology workflow solutions. Dianne emphasizes the importance of understanding the clinical side, building trust with referring physicians, and advocating for women's imaging. Dianne shares her experiences in scaling radiology programs, fostering relationships with gynecologists, and ensuring breast care programs are integral to the growing Cancer Institute. Dianne also discusses her transition to Abbadox, highlighting the company's mission to improve the work lives of healthcare professionals through integrated workflow solutions. The conversation concludes with insights into the future of healthcare and radiology, emphasizing the need to adapt to technological advancements, streamline processes, and maintain a strong commitment to patient care.

Today's guest is Dr. Faraz Harsini. He's a cultivated meat bioprocessing scientist at the Good Food Institute and the founder and CEO of Allied Scholars for Animal Protection – a nonprofit that supports and mentors student advocates and future vegan leaders for the abolition of cruelty to humans and nonhumans. Dr. Harsini appeared on the podcast in episode 256, in which we discussed his upbringing in Iran as a member of the LGBT community, his advocacy work on college campuses, and a myriad of social justice issues, but the conversation was so powerful, and there was so much ground we didn't get to cover, especially about his current work, that we had to have him back.    So whether or not you listened to the first part of our interview with him, you definitely want to stay with us as we tackle some serious topical issues that pertain to everyone.   “I guess the reason that I promote a plant-based diet and veganism full-time today is because I did my entire master's on cancer, and I worked on proteins involving cancer. And the fact that nobody ever mentioned diet at all, like I'm not talking about my research, no one, even those textbooks. And it had to come as a surprise to me when I like had to learn it by myself, and then you looked at it and you realized that every single Cancer Institute in the world says the less meat you eat, the better. Every single Cancer Institute in the world, and some even include Dairy and other types of meat, but when it comes to processed and unprocessed red meat, every single Cancer Institute in the world says the less meat you eat, the better.” - Dr. Faraz Harsini   What we discuss in this episode: - The complete protein myth and why plants are such a powerful source of protein. - What happens when you cook and eat red meat? - The benefits of cultivated meat production. - The dangers posed to humans from animal experimentation. - The cruelty Dr. Harsini witnessed while visiting a dairy farm in Texas. - Dr. Harsini's thoughts on changing our food system. - The importance of speaking up as a vegan.   Resources: - Dr. Harsini's website: Dr. Faraz Harsini - ASAP's website: Allied Scholars for Animal Protection - Good Food Institute: Faraz Harsini, M.Sc., Ph.D. - The Good Food Institute - Dr. Harsini's Instagram: Dr. Faraz Harsini (@dr_faraz_harsini) • Instagram photos and videos - Twitter: https://twitter.com/DrFarazHarsini - YouTube: Dr. Faraz Harsini - YouTube - Animal Activism Mentorship - https://animalactivismmentorship.com/   ★☆★ Click the link below to support the ADD SOY Act! ★☆★ https://switch4good.org/add-soy-act/ ★☆★ Share the website and get your resources here ★☆★ https://kidsandmilk.org/ ★☆★ Send us a voice message and ask a question. We want to hear from you! ★☆★ https://switch4good.org/podcast/ ★☆★ Dairy-Free Swaps Guide: Easy Anti-Inflammatory Meals, Recipes, and Tips ★☆★ https://switch4good.org/dairy-free-swaps-guide ★☆★SUPPORT SWITCH4GOOD★☆★ https://switch4good.org/support-us/ ★☆★ JOIN OUR PRIVATE FACEBOOK GROUP ★☆★  https://www.facebook.com/groups/podcastchat ★☆★ SWITCH4GOOD WEBSITE ★☆★ https://switch4good.org/ ★☆★ ONLINE STORE ★☆★ https://shop.switch4good.org/shop/ ★☆★ FOLLOW US ON INSTAGRAM ★☆★ https://www.instagram.com/Switch4Good/ ★☆★ LIKE US ON FACEBOOK ★☆★ https://www.facebook.com/Switch4Good/ ★☆★ FOLLOW US ON TWITTER ★☆★ https://mobile.twitter.com/Switch4GoodNFT ★☆★ AMAZON STORE ★☆★ https://www.amazon.com/shop/switch4good ★☆★ DOWNLOAD THE ABILLION APP ★☆★ https://app.abillion.com/users/switch4good

1. 'RHOA' Alum Cynthia Bailey & Husband Split (TMZ) 2. 'Glee' Controversies Explored in Discovery+ Docuseries From Ample Entertainment (Deadline) 3. Anne Hathaway Says Her 'Devil Wears Prada Look' at NYFW Was an 'Accident': 'It Was Kind of Nuts' (PEOPLE) 4. Heidi Klum and daughter Leni, 18, slammed for 'weird' and 'disturbing' lingerie ad (NY Post) 5. 'RHOBH' star Lisa Rinna slammed by Cancer Institute over finale comments (Page Six) The Toast with Jackie (@JackieOshry) and Claudia Oshry (@girlwithnojob)  NLOG Tickets: https://www.girlwithnojob.com/tour Merch: https://www.shopmorningtoast.com/ The Toast Patreon: https://www.patreon.com/themorningtoast Girl With No Job by Claudia Oshry: https://www.girlwithnojob.com/book